Celgene Cp Cvr (CELGZ) 1.14 $CELGZ
Celgene Reports Second Quarter 2016 Operating and Financial Results
BusinessWire - Thu Jul 28, 6:30AM CDT
--- REVLIMID(R) Net Product Sales $1.7B in Q2:16; Increased 18% Y/Y
CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)
Celgene and LYSARC Provide Update on the Phase III 'REMARC' Study of REVLIMID(R) Maintenance Treatment in Patients with Diffuse Large B-Cell Lymphoma Responding to First-Line R-CHOP Therapy
BusinessWire - Mon Jul 25, 3:30PM CDT
Celgene Corporation (NASDAQ: CELG) and the Lymphoma Study Association (LYSA) today announced that the Lymphoma Academic Research Organisation (LYSARC) reported initial data from a phase III, randomized, double-blind, international clinical study (REMARC). This investigational study evaluated maintenance therapy with REVLIMID(R) (lenalidomide) compared with placebo in diffuse large B-cell lymphoma (DLBCL) patients responding to first-line rituximab plus CHOP chemotherapy (R-CHOP) induction therapy. LYSARC sponsored the study under a Clinical Trial Agreement with Celgene.
CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)
Global Systemic Psoriasis Therapeutics Market 2016-2020 - Dominance of Market by Biologics - Key Vendors are AbbVie, Celgene & Amgen - Research and Markets
BusinessWire - Mon Jul 25, 9:02AM CDT
Research and Markets has announced the addition of the "Global Systemic Psoriasis Therapeutics Market 2016-2020" report to their offering.
AMGN: 174.16 (+2.13), CELGZ: 1.14 (-0.02)
REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Relapsed/Refractory Patients with Mantle Cell Lymphoma
BusinessWire - Fri Jul 15, 1:00AM CDT
--Approval gives Celgene its first opportunity to support unmet needs of lymphoma patients across the European Union
CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)
Research and Markets - Global Solid Tumors Drugs Market 2016-2020 - Key Vendors are F. Hoffmann-La Roche, Novartis, Celgene, Johnson & Johnson, Pfizer & BMS
PR Newswire Europe - Thu Jul 14, 10:11AM CDT
DUBLIN, July 14, 2016 /PRNewswire/ --
JNJ: 125.40 (+0.17), CELGZ: 1.14 (-0.02)
Biotechnology Equities Under the Scanner - Exelixis, Novavax, Celgene, and Ariad Pharma
PR Newswire - Thu Jul 07, 7:00AM CDT
On Wednesday, July 06, 2016, the NASDAQ Composite ended the trading session at 4,859.16, up 0.75%; the Dow Jones Industrial Average edged 0.44% higher, to finish at 17,918.62; and the S&P 500 closed at 2,099.73, up 0.54%. The gains were broad based as eight out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Novavax Inc. (NASDAQ: NVAX), Celgene Corporation (NASDAQ: CELG), and Ariad Pharmaceuticals Inc. (NASDAQ: ARIA). Learn more about these stocks by accessing their free notes at:
NVAX: 7.35 (+0.03), ARIA: 9.71 (+0.20), CELG: 114.69 (+2.50), EXEL: 9.27 (+0.09), CELGZ: 1.14 (-0.02)
Learn how to target an 20% return on Chipotle Mexican Grill, or get option-trade ideas on Amgen, Celgene, Google Inc., and SolarEdge Technologies or any stock you choose
PR Newswire - Thu Jun 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMGN, CELG, CMG, GOOG, and SEDG.
SEDG: 17.19 (-0.71), CMG: 414.08 (-9.91), AMGN: 174.16 (+2.13), GOOGL: 800.94 (+9.60), GOOG: 772.88 (+4.09), CELGZ: 1.14 (-0.02), CELG: 114.69 (+2.50)
The Quest for an Effective Treatment for Pancreatic Cancer
ACCESSWIRE - Wed Jun 22, 7:16AM CDT
WINDSOR, ON / ACCESSWIRE / June 22, 2016 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, would like to highlight a couple of companies that we believe have immense potential in the quest for an effective pancreatic cancer treatment.
BLCM: 16.04 (+0.16), CELGZ: 1.14 (-0.02)
Global Stem Cell Therapy Market Worth USD 1.87 Billion by 2025 - Analysis, Technologies & Forecasts Report 2016-2025 - Key Vendors: Advanced Cell Technologies, Celgene Corp, Gamida Cell - Research and Markets
BusinessWire - Fri Jun 17, 11:26AM CDT
Research and Markets has announced the addition of the "Global Stem Cell Therapy Market Analysis & Trends - Industry Forecast to 2025" report to their offering.
CELGZ: 1.14 (-0.02)
Celgene Announces Additional $3 Billion Share Repurchase Authorization
BusinessWire - Wed Jun 15, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that during its June meeting the Company's Board of Directors authorized the repurchase of up to an additional $3.0 billion of the Company's common stock.
CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Beta-Thalassemia Presented at the 21st Congress of the European Hematology Association
BusinessWire - Fri Jun 10, 6:00AM CDT
--in patients with beta-thalassemia -
XLRN: 34.40 (+0.48), CELGZ: 1.14 (-0.02)
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 21st Congress of the European Hematology Association
BusinessWire - Fri Jun 10, 6:00AM CDT
--- Acceleron to host conference call and live webcast today at 8:00 a.m. EDT (2:00 p.m. CEST) -
XLRN: 34.40 (+0.48), CELGZ: 1.14 (-0.02), CELG: 114.69 (+2.50)
Celgene Announces Presentations of Investigational Studies in Blood Cancers at EHA 2016
BusinessWire - Thu Jun 09, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that more than 40 presentations reporting on investigational studies in blood cancers will be presented during the 21st European Hematology Association annual meeting in Copenhagen, Denmark, from June 9-12, 2016.
CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)
Study Reveals Racial Disparities in Multiple Myeloma Treatment Patterns
BusinessWire - Tue Jun 07, 3:05PM CDT
Celgene Corporation (NASDAQ:CELG) today announced the presentation of a study comparing treatment patterns, healthcare costs and overall survival between African American and Caucasian Medicare beneficiaries with newly diagnosed multiple myeloma. The study, which was presented by Dr. Sikander Ailawadhi of the Mayo Clinic at a poster session during the 52nd ASCO Annual Meeting in Chicago, Ill, discussed disparities observed in treatment initiation between the two studied populations and the impact of these disparities on patient outcomes.
CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)
Data Presented at ASCO 2016 Builds upon Foundation of Abraxane(R) Plus Gemcitabine as a First-Line Treatment in Patients with Metastatic Pancreatic Cancer
BusinessWire - Sat Jun 04, 4:32PM CDT
Celgene Corporation (NASDAQ:CELG) today announced that results from multiple sponsored and independent studies presented during the 52nd ASCO Annual Meeting evaluated the use of ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) in combination with gemcitabine in first-line metastatic pancreatic cancer.
CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)
Pooled Data from Meta-Analysis Suggest Significant Overall Survival Benefit of Investigational REVLIMID(R) Maintenance Following Autologous Stem Cell Transplant in Multiple Myeloma
BusinessWire - Fri Jun 03, 3:59PM CDT
Celgene Corporation (NASDAQ:CELG) today announced data from a meta-analysis of overall survival in multiple myeloma (MM) patients receiving investigational maintenance treatment with REVLIMID(R) (lenalidomide) capsules following high-dose melphalan and autologous stem cell transplant (ASCT) were presented during the 52nd ASCO Annual Meeting in Chicago, Illinois. The analysis, based on data from studies conducted by the Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group
with support from the National Cancer Institute, Intergroupe Francophone du Myelome (IFM) and the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), was presented by Dr. Philip McCarthy of Roswell Park Cancer Institute and lead investigator of the CALGB (Alliance) 100104 study. The findings demonstrated significantly prolonged overall survival (OS) compared to the control arm of placebo or no maintenance.
CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)
Mylan Launches Generic Vidaza® Injection
PR Newswire - Thu Jun 02, 6:30AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Azacitidine for Injection, 100 mg/vial, which is a generic version of Celgene's Vidaza® Injection, 100 mg/vial. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Azacitidine for Injection is a nucleoside metabolic inhibitor indicated for the treatment of the five French-American-British (FAB) subtypes of myelodysplastic syndrome, a blood cell disorder that can occur as a result of cancer treatments or can progress to leukemia.
MYL: 46.74 (-0.05), CELGZ: 1.14 (-0.02)
The Newly Launched IL-17 Inhibitor Cosentyx is Gradually Gaining Momentum in the EU5, While Established Subcutaneous TNF-Alpha Inhibitors Humira and Enbrel Continue to Dominate Biologics Patient Share in Psoriasis
PR Newswire - Wed Jun 01, 9:08AM CDT
Decision Resources Group finds that in the EU5, while surveyed dermatologists prefer subcutaneous TNF-alpha inhibitors AbbVie's Humira and Amgen/Pfizer's Enbrel for first-line treatment, Janssen Biotech's Stelara is also seeing increasing use in earlier-lines of therapy, driven by favorable efficacy and safety, increasing physician familiarity and convenient dosing. Among the biologics, Humira is the patient share leader, followed by Enbrel and Stelara. However, Novartis's Cosentyx, the first-in-class IL-17 inhibitor, has steadily captured market share as it gradually becomes available to dermatologists in the EU5. Celgene's Otezla, an oral PDE-4 inhibitor, is seeing only limited usage in moderate and severe patients probably because its access is limited across the EU5. However, unlike biologics, it is seeing comparable use in both the moderate and severe sub-populations.
NVS: 83.07 (-0.19), CELGZ: 1.14 (-0.02)
InvestorsObserver releases covered-call reports for GoPro, Verizon Communications, Vertex Pharmaceuticals, NVIDIA and Celgene
PR Newswire - Tue May 31, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GPRO, VZ, VRTX, NVDA and CELG.
GPRO: 12.94 (+0.30), VRTX: 98.20 (+1.20), VZ: 54.50 (-0.91), NVDA: 56.73 (-0.37), CELGZ: 1.14 (-0.02), CELG: 114.69 (+2.50)
Ulcerative Colitis - Pipeline Review, H1 2016 - Key Players Include Amgen, Gilead Sciences & Celgene Corporation - Research and Markets
BusinessWire - Fri May 27, 4:43AM CDT
Research and Markets has announced the addition of the "Ulcerative Colitis - Pipeline Review, H1 2016" report to their offering.
GILD: 80.46 (+0.99), CELGZ: 1.14 (-0.02)
Celgene Reports Second Quarter 2016 Operating and Financial Results
BusinessWire - Thu Jul 28, 6:30AM CDT
--- REVLIMID(R) Net Product Sales $1.7B in Q2:16; Increased 18% Y/Y
CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)
Celgene and LYSARC Provide Update on the Phase III 'REMARC' Study of REVLIMID(R) Maintenance Treatment in Patients with Diffuse Large B-Cell Lymphoma Responding to First-Line R-CHOP Therapy
BusinessWire - Mon Jul 25, 3:30PM CDT
Celgene Corporation (NASDAQ: CELG) and the Lymphoma Study Association (LYSA) today announced that the Lymphoma Academic Research Organisation (LYSARC) reported initial data from a phase III, randomized, double-blind, international clinical study (REMARC). This investigational study evaluated maintenance therapy with REVLIMID(R) (lenalidomide) compared with placebo in diffuse large B-cell lymphoma (DLBCL) patients responding to first-line rituximab plus CHOP chemotherapy (R-CHOP) induction therapy. LYSARC sponsored the study under a Clinical Trial Agreement with Celgene.
CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)
Global Systemic Psoriasis Therapeutics Market 2016-2020 - Dominance of Market by Biologics - Key Vendors are AbbVie, Celgene & Amgen - Research and Markets
BusinessWire - Mon Jul 25, 9:02AM CDT
Research and Markets has announced the addition of the "Global Systemic Psoriasis Therapeutics Market 2016-2020" report to their offering.
AMGN: 174.16 (+2.13), CELGZ: 1.14 (-0.02)
REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Relapsed/Refractory Patients with Mantle Cell Lymphoma
BusinessWire - Fri Jul 15, 1:00AM CDT
--Approval gives Celgene its first opportunity to support unmet needs of lymphoma patients across the European Union
CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)
Research and Markets - Global Solid Tumors Drugs Market 2016-2020 - Key Vendors are F. Hoffmann-La Roche, Novartis, Celgene, Johnson & Johnson, Pfizer & BMS
PR Newswire Europe - Thu Jul 14, 10:11AM CDT
DUBLIN, July 14, 2016 /PRNewswire/ --
JNJ: 125.40 (+0.17), CELGZ: 1.14 (-0.02)
Biotechnology Equities Under the Scanner - Exelixis, Novavax, Celgene, and Ariad Pharma
PR Newswire - Thu Jul 07, 7:00AM CDT
On Wednesday, July 06, 2016, the NASDAQ Composite ended the trading session at 4,859.16, up 0.75%; the Dow Jones Industrial Average edged 0.44% higher, to finish at 17,918.62; and the S&P 500 closed at 2,099.73, up 0.54%. The gains were broad based as eight out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Novavax Inc. (NASDAQ: NVAX), Celgene Corporation (NASDAQ: CELG), and Ariad Pharmaceuticals Inc. (NASDAQ: ARIA). Learn more about these stocks by accessing their free notes at:
NVAX: 7.35 (+0.03), ARIA: 9.71 (+0.20), CELG: 114.69 (+2.50), EXEL: 9.27 (+0.09), CELGZ: 1.14 (-0.02)
Learn how to target an 20% return on Chipotle Mexican Grill, or get option-trade ideas on Amgen, Celgene, Google Inc., and SolarEdge Technologies or any stock you choose
PR Newswire - Thu Jun 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMGN, CELG, CMG, GOOG, and SEDG.
SEDG: 17.19 (-0.71), CMG: 414.08 (-9.91), AMGN: 174.16 (+2.13), GOOGL: 800.94 (+9.60), GOOG: 772.88 (+4.09), CELGZ: 1.14 (-0.02), CELG: 114.69 (+2.50)
The Quest for an Effective Treatment for Pancreatic Cancer
ACCESSWIRE - Wed Jun 22, 7:16AM CDT
WINDSOR, ON / ACCESSWIRE / June 22, 2016 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, would like to highlight a couple of companies that we believe have immense potential in the quest for an effective pancreatic cancer treatment. BLCM: 16.04 (+0.16), CELGZ: 1.14 (-0.02)
Global Stem Cell Therapy Market Worth USD 1.87 Billion by 2025 - Analysis, Technologies & Forecasts Report 2016-2025 - Key Vendors: Advanced Cell Technologies, Celgene Corp, Gamida Cell - Research and Markets
BusinessWire - Fri Jun 17, 11:26AM CDT
Research and Markets has announced the addition of the "Global Stem Cell Therapy Market Analysis & Trends - Industry Forecast to 2025" report to their offering.
CELGZ: 1.14 (-0.02)
Celgene Announces Additional $3 Billion Share Repurchase Authorization
BusinessWire - Wed Jun 15, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that during its June meeting the Company's Board of Directors authorized the repurchase of up to an additional $3.0 billion of the Company's common stock.
CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Beta-Thalassemia Presented at the 21st Congress of the European Hematology Association
BusinessWire - Fri Jun 10, 6:00AM CDT
--in patients with beta-thalassemia -
XLRN: 34.40 (+0.48), CELGZ: 1.14 (-0.02)
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 21st Congress of the European Hematology Association
BusinessWire - Fri Jun 10, 6:00AM CDT
--- Acceleron to host conference call and live webcast today at 8:00 a.m. EDT (2:00 p.m. CEST) -
XLRN: 34.40 (+0.48), CELGZ: 1.14 (-0.02), CELG: 114.69 (+2.50)
Celgene Announces Presentations of Investigational Studies in Blood Cancers at EHA 2016
BusinessWire - Thu Jun 09, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that more than 40 presentations reporting on investigational studies in blood cancers will be presented during the 21st European Hematology Association annual meeting in Copenhagen, Denmark, from June 9-12, 2016.
CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)
Study Reveals Racial Disparities in Multiple Myeloma Treatment Patterns
BusinessWire - Tue Jun 07, 3:05PM CDT
Celgene Corporation (NASDAQ:CELG) today announced the presentation of a study comparing treatment patterns, healthcare costs and overall survival between African American and Caucasian Medicare beneficiaries with newly diagnosed multiple myeloma. The study, which was presented by Dr. Sikander Ailawadhi of the Mayo Clinic at a poster session during the 52nd ASCO Annual Meeting in Chicago, Ill, discussed disparities observed in treatment initiation between the two studied populations and the impact of these disparities on patient outcomes.
CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)
Data Presented at ASCO 2016 Builds upon Foundation of Abraxane(R) Plus Gemcitabine as a First-Line Treatment in Patients with Metastatic Pancreatic Cancer
BusinessWire - Sat Jun 04, 4:32PM CDT
Celgene Corporation (NASDAQ:CELG) today announced that results from multiple sponsored and independent studies presented during the 52nd ASCO Annual Meeting evaluated the use of ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) in combination with gemcitabine in first-line metastatic pancreatic cancer.
CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)
Pooled Data from Meta-Analysis Suggest Significant Overall Survival Benefit of Investigational REVLIMID(R) Maintenance Following Autologous Stem Cell Transplant in Multiple Myeloma
BusinessWire - Fri Jun 03, 3:59PM CDT
Celgene Corporation (NASDAQ:CELG) today announced data from a meta-analysis of overall survival in multiple myeloma (MM) patients receiving investigational maintenance treatment with REVLIMID(R) (lenalidomide) capsules following high-dose melphalan and autologous stem cell transplant (ASCT) were presented during the 52nd ASCO Annual Meeting in Chicago, Illinois. The analysis, based on data from studies conducted by the Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group
with support from the National Cancer Institute, Intergroupe Francophone du Myelome (IFM) and the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), was presented by Dr. Philip McCarthy of Roswell Park Cancer Institute and lead investigator of the CALGB (Alliance) 100104 study. The findings demonstrated significantly prolonged overall survival (OS) compared to the control arm of placebo or no maintenance. CELG: 114.69 (+2.50), CELGZ: 1.14 (-0.02)
Mylan Launches Generic Vidaza® Injection
PR Newswire - Thu Jun 02, 6:30AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Azacitidine for Injection, 100 mg/vial, which is a generic version of Celgene's Vidaza® Injection, 100 mg/vial. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Azacitidine for Injection is a nucleoside metabolic inhibitor indicated for the treatment of the five French-American-British (FAB) subtypes of myelodysplastic syndrome, a blood cell disorder that can occur as a result of cancer treatments or can progress to leukemia.
MYL: 46.74 (-0.05), CELGZ: 1.14 (-0.02)
The Newly Launched IL-17 Inhibitor Cosentyx is Gradually Gaining Momentum in the EU5, While Established Subcutaneous TNF-Alpha Inhibitors Humira and Enbrel Continue to Dominate Biologics Patient Share in Psoriasis
PR Newswire - Wed Jun 01, 9:08AM CDT
Decision Resources Group finds that in the EU5, while surveyed dermatologists prefer subcutaneous TNF-alpha inhibitors AbbVie's Humira and Amgen/Pfizer's Enbrel for first-line treatment, Janssen Biotech's Stelara is also seeing increasing use in earlier-lines of therapy, driven by favorable efficacy and safety, increasing physician familiarity and convenient dosing. Among the biologics, Humira is the patient share leader, followed by Enbrel and Stelara. However, Novartis's Cosentyx, the first-in-class IL-17 inhibitor, has steadily captured market share as it gradually becomes available to dermatologists in the EU5. Celgene's Otezla, an oral PDE-4 inhibitor, is seeing only limited usage in moderate and severe patients probably because its access is limited across the EU5. However, unlike biologics, it is seeing comparable use in both the moderate and severe sub-populations.
NVS: 83.07 (-0.19), CELGZ: 1.14 (-0.02)
InvestorsObserver releases covered-call reports for GoPro, Verizon Communications, Vertex Pharmaceuticals, NVIDIA and Celgene
PR Newswire - Tue May 31, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GPRO, VZ, VRTX, NVDA and CELG.
GPRO: 12.94 (+0.30), VRTX: 98.20 (+1.20), VZ: 54.50 (-0.91), NVDA: 56.73 (-0.37), CELGZ: 1.14 (-0.02), CELG: 114.69 (+2.50)
Ulcerative Colitis - Pipeline Review, H1 2016 - Key Players Include Amgen, Gilead Sciences & Celgene Corporation - Research and Markets
BusinessWire - Fri May 27, 4:43AM CDT
Research and Markets has announced the addition of the "Ulcerative Colitis - Pipeline Review, H1 2016" report to their offering.
GILD: 80.46 (+0.99), CELGZ: 1.14 (-0.02)
